Marinus Pharmaceuticals (NASDAQ:MRNS) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report issued on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

MRNS has been the topic of a number of other research reports. Royal Bank of Canada cut their price target on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research note on Friday, October 25th. TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. JMP Securities restated a “market perform” rating on shares of Marinus Pharmaceuticals in a research report on Thursday, October 24th. Truist Financial cut Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. Finally, EF Hutton Acquisition Co. I raised shares of Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Marinus Pharmaceuticals has an average rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Price Performance

MRNS opened at $0.55 on Tuesday. Marinus Pharmaceuticals has a fifty-two week low of $0.22 and a fifty-two week high of $10.50. The company has a market cap of $30.09 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. The firm has a 50 day simple moving average of $0.38 and a 200 day simple moving average of $0.98.

Institutional Trading of Marinus Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Suvretta Capital Management LLC boosted its holdings in shares of Marinus Pharmaceuticals by 32.8% in the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock valued at $8,930,000 after buying an additional 1,253,901 shares during the period. Franklin Resources Inc. lifted its position in Marinus Pharmaceuticals by 34.9% in the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after acquiring an additional 1,219,871 shares in the last quarter. abrdn plc boosted its stake in Marinus Pharmaceuticals by 146.1% in the 3rd quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after purchasing an additional 1,578,329 shares during the period. GSA Capital Partners LLP boosted its stake in Marinus Pharmaceuticals by 409.4% in the 3rd quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after purchasing an additional 817,050 shares during the period. Finally, Renaissance Technologies LLC bought a new position in Marinus Pharmaceuticals during the 2nd quarter worth about $727,000. 98.80% of the stock is currently owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.